<DOC>
	<DOCNO>NCT02729766</DOCNO>
	<brief_summary>Empagliflozin ( Jardiance ) ® sodium glucose co-transporter 2 ( SGLT2 ) -Inhibitor , new treatment option develop patient diabetes mellitus type 2 . The SGLT2 express proximal tubule reabsorb approximately 90 percent filter glucose . The inhibition SGLT2 result renal excretion glucose subsequent osmotic diuresis . This mechanism could result therapeutic effect patient hypotonic hyponatremia syndrome inappropriate antidiuretic hormone ( ADH ) secretion ( SIAD ) . Because patient SIAD usually several comorbidities different medication , study investigate physiological effect difficult interpret . Therefore model study possible physiological effect SGLT2-inhibitors hypotonic hyponatremia SIAD need . The aim study evaluate whether empagliflozin ( Jardiance ) ® effect serum sodium level healthy volunteer induce hypotonic hyponatremia .</brief_summary>
	<brief_title>Effects Empagliflozin SGLT2-Inhibitor Healthy Volunteers With Induced Hypotonic Hyponatremia - DIVE Study</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Informed consent document signature Age 18 65 year serum sodium level 135145mmol/l clinically euvolemic status Known suspect allergy trial product relate product Pregnancy breast feeding Inability follow procedure study , e.g . due language problem , psychological disorder , dementia , etc . participant Participation another study investigational drug within 30 day precede present study Enrolment investigator , his/her family member , employee dependent person untreated hypothyroidism cortisol deficiency history heart failure liver cirrhosis stage kidney disease ( GFR &lt; 60ml/min ) epileptic seizure within last year uncontrolled hypertension ( systolic blood pressure &gt; 160mmHg ) Diabetes mellitus type 1 2 BMI &lt; 18 &gt; 29kg/m2 severe disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hyponatremia</keyword>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>